Adam Mourad Chekroud1, Ryan Joseph Zotti2, Zarrar Shehzad3, Ralitza Gueorguieva4, Marcia K Johnson3, Madhukar H Trivedi5, Tyrone D Cannon6, John Harrison Krystal7, Philip Robert Corlett7. 1. Department of Psychology, Yale University, New Haven, CT, USA; Centre for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, USA. Electronic address: adam.chekroud@yale.edu. 2. Capital One, McLean, VA, USA. 3. Department of Psychology, Yale University, New Haven, CT, USA. 4. Department of Biostatistics, Yale University, New Haven, CT, USA. 5. Department of Psychiatry, UT Southwestern, Dallas, TX, USA. 6. Department of Psychology, Yale University, New Haven, CT, USA; Department of Psychiatry, Yale University, New Haven, CT, USA. 7. Department of Psychiatry, Yale University, New Haven, CT, USA.
Abstract
BACKGROUND: Antidepressant treatment efficacy is low, but might be improved by matching patients to interventions. At present, clinicians have no empirically validated mechanisms to assess whether a patient with depression will respond to a specific antidepressant. We aimed to develop an algorithm to assess whether patients will achieve symptomatic remission from a 12-week course of citalopram. METHODS: We used patient-reported data from patients with depression (n=4041, with 1949 completers) from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D; ClinicalTrials.gov, number NCT00021528) to identify variables that were most predictive of treatment outcome, and used these variables to train a machine-learning model to predict clinical remission. We externally validated the model in the escitalopram treatment group (n=151) of an independent clinical trial (Combining Medications to Enhance Depression Outcomes [COMED]; ClinicalTrials.gov, number NCT00590863). FINDINGS: We identified 25 variables that were most predictive of treatment outcome from 164 patient-reportable variables, and used these to train the model. The model was internally cross-validated, and predicted outcomes in the STAR*D cohort with accuracy significantly above chance (64·6% [SD 3·2]; p<0·0001). The model was externally validated in the escitalopram treatment group (N=151) of COMED (accuracy 59·6%, p=0.043). The model also performed significantly above chance in a combined escitalopram-buproprion treatment group in COMED (n=134; accuracy 59·7%, p=0·023), but not in a combined venlafaxine-mirtazapine group (n=140; accuracy 51·4%, p=0·53), suggesting specificity of the model to underlying mechanisms. INTERPRETATION: Building statistical models by mining existing clinical trial data can enable prospective identification of patients who are likely to respond to a specific antidepressant. FUNDING: Yale University.
RCT Entities:
BACKGROUND: Antidepressant treatment efficacy is low, but might be improved by matching patients to interventions. At present, clinicians have no empirically validated mechanisms to assess whether a patient with depression will respond to a specific antidepressant. We aimed to develop an algorithm to assess whether patients will achieve symptomatic remission from a 12-week course of citalopram. METHODS: We used patient-reported data from patients with depression (n=4041, with 1949 completers) from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D; ClinicalTrials.gov, number NCT00021528) to identify variables that were most predictive of treatment outcome, and used these variables to train a machine-learning model to predict clinical remission. We externally validated the model in the escitalopram treatment group (n=151) of an independent clinical trial (Combining Medications to Enhance Depression Outcomes [COMED]; ClinicalTrials.gov, number NCT00590863). FINDINGS: We identified 25 variables that were most predictive of treatment outcome from 164 patient-reportable variables, and used these to train the model. The model was internally cross-validated, and predicted outcomes in the STAR*D cohort with accuracy significantly above chance (64·6% [SD 3·2]; p<0·0001). The model was externally validated in the escitalopram treatment group (N=151) of COMED (accuracy 59·6%, p=0.043). The model also performed significantly above chance in a combined escitalopram-buproprion treatment group in COMED (n=134; accuracy 59·7%, p=0·023), but not in a combined venlafaxine-mirtazapine group (n=140; accuracy 51·4%, p=0·53), suggesting specificity of the model to underlying mechanisms. INTERPRETATION: Building statistical models by mining existing clinical trial data can enable prospective identification of patients who are likely to respond to a specific antidepressant. FUNDING: Yale University.
Authors: Sarah Graham; Colin Depp; Ellen E Lee; Camille Nebeker; Xin Tu; Ho-Cheol Kim; Dilip V Jeste Journal: Curr Psychiatry Rep Date: 2019-11-07 Impact factor: 5.285
Authors: David Chen; Naveed Afzal; Sunghwan Sohn; Elizabeth B Habermann; James M Naessens; David W Larson; Hongfang Liu Journal: Surgery Date: 2018-07-20 Impact factor: 3.982
Authors: Susel Góngora Alonso; Isabel de la Torre-Díez; Sofiane Hamrioui; Miguel López-Coronado; Diego Calvo Barreno; Lola Morón Nozaleda; Manuel Franco Journal: J Med Syst Date: 2018-07-21 Impact factor: 4.460
Authors: Mario Maj; Dan J Stein; Gordon Parker; Mark Zimmerman; Giovanni A Fava; Marc De Hert; Koen Demyttenaere; Roger S McIntyre; Thomas Widiger; Hans-Ulrich Wittchen Journal: World Psychiatry Date: 2020-10 Impact factor: 49.548